BLAINJECTIONINJECTABLE
Approved
Dec 2020
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
MARGENZA (margetuximab-cmkb) by MacroGenics is her2/neu/cerbb2 antagonists [moa]. Approved for her2/neu receptor antagonist [epc]. First approved in 2020.
Drug data last refreshed 12h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MARGENZA (margetuximab-cmkb) is a monoclonal antibody antagonist targeting HER2/neu receptors, approved by the FDA in December 2020 for HER2-positive breast cancer. It is engineered with an enhanced Fc region designed to improve immune cell engagement compared to earlier-generation HER2-directed antibodies. The drug represents MacroGenics' entry into the competitive HER2 oncology space.
Peak
The product is at peak commercial stage with moderate competitive pressure (30), indicating active promotion and team engagement, though growth trajectory and team expansion outlook are constrained by established competitor dominance.
Mechanism of Action
HER2/Neu/cerbB2 Antagonists
Pharmacologic Class:
HER2/neu Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MARGENZA represents a niche opportunity within the established HER2 oncology market, with limited current headcount and job availability reflecting its modest market share and competitive positioning. Roles on this brand are concentrated in commercial and market access functions rather than clinical development, making it suitable for professionals focused on managed care and hospital formulary strategy in oncology.
Brand Manager
Worked on MARGENZA at MacroGenics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.